| dc.contributor |
Massachusetts Institute of Technology. Department of Biological Engineering |
|
| dc.contributor |
Massachusetts Institute of Technology. Department of Biology |
|
| dc.contributor |
Pishesha, Novalia |
|
| dc.contributor |
Wibowo, Marsha C |
|
| dc.contributor |
Dhesycka, Rhogerry |
|
| dc.contributor |
Bousbaine, Djenet |
|
| dc.contributor |
Lodish, Harvey F |
|
| dc.contributor |
Ploegh, Hidde |
|
| dc.creator |
Bilate, Angelina M. |
|
| dc.creator |
Huang, Nai-Jia |
|
| dc.creator |
Li, Hojun |
|
| dc.creator |
Patterson, Heide C. |
|
| dc.creator |
Dougan, Stephanie K. |
|
| dc.creator |
Maruyama, Takeshi |
|
| dc.creator |
Pishesha, Novalia |
|
| dc.creator |
Wibowo, Marsha C |
|
| dc.creator |
Dhesycka, Rhogerry |
|
| dc.creator |
Bousbaine, Djenet |
|
| dc.creator |
Lodish, Harvey F |
|
| dc.creator |
Ploegh, Hidde |
|
| dc.creator |
Li, Zeyang,S.M.Massachusetts Institute of Technology. |
|
| dc.date |
2018-01-18T17:23:38Z |
|
| dc.date |
2018-01-18T17:23:38Z |
|
| dc.date |
2017-03 |
|
| dc.date |
2016-10 |
|
| dc.date |
2018-01-16T19:31:27Z |
|
| dc.date.accessioned |
2023-03-01T18:08:05Z |
|
| dc.date.available |
2023-03-01T18:08:05Z |
|
| dc.identifier |
0027-8424 |
|
| dc.identifier |
1091-6490 |
|
| dc.identifier |
http://hdl.handle.net/1721.1/113222 |
|
| dc.identifier |
Pishesha, Novalia et al. “Engineered Erythrocytes Covalently Linked to Antigenic Peptides Can Protect Against Autoimmune Disease.” Proceedings of the National Academy of Sciences 114, 12 (March 2017): 3157–3162 © 2017 National Academy of Sciences |
|
| dc.identifier |
https://orcid.org/0000-0001-9306-8271 |
|
| dc.identifier |
https://orcid.org/0000-0003-2683-9544 |
|
| dc.identifier |
https://orcid.org/0000-0002-7029-7415 |
|
| dc.identifier |
https://orcid.org/0000-0002-1090-6071 |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/278879 |
|
| dc.description |
Current therapies for autoimmune diseases rely on traditional immunosuppressive medications that expose patients to an increased risk of opportunistic infections and other complications. Immunoregulatory interventions that act prophylactically or therapeutically to induce antigen-specific tolerance might overcome these obstacles. Here we use the transpeptidase sortase to covalently attach diseaseassociated autoantigens to genetically engineered and to unmodified red blood cells as a means of inducing antigen-specific tolerance. This approach blunts the contribution to immunity of major subsets of immune effector cells (B cells, CD4⁺ and CD8⁺ T cells) in an antigenspecific manner. Transfusion of red blood cells expressing self-antigen epitopes can alleviate and even prevent signs of disease in experimental autoimmune encephalomyelitis, as well as maintain normoglycemia in a mouse model of type 1 diabetes. |
|
| dc.description |
United States. Defense Advanced Research Projects Agency (Contract HR0011-12-2-0015) |
|
| dc.format |
application/octet-stream |
|
| dc.publisher |
National Academy of Sciences (U.S.) |
|
| dc.relation |
http://dx.doi.org/10.1073/PNAS.1701746114 |
|
| dc.relation |
Proceedings of the National Academy of Sciences |
|
| dc.rights |
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. |
|
| dc.source |
PNAS |
|
| dc.title |
Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease |
|
| dc.type |
Article |
|
| dc.type |
http://purl.org/eprint/type/JournalArticle |
|